923010-21-3

Upstream product

• 122-78-1 phenylacetaldehyde 
• 923010-20-2 methyl 2-[(tert-butoxycarbonyl)amino]-5-phenylthiophene-3-carboxylate 

Downstream Products

• 1240361-33-4 C₂₃H₂₇N₃O₄S 
• 1240361-35-6 C₂₄H₂₇N₃O₃S 
• 1240361-31-2 C₂₁H₂₃N₃O₄S 
• 1240361-29-8 C₂₆H₂₇N₃O₃S 
• 1240361-27-6 C₂₁H₂₅N₃O₄S 
• 1240361-25-4 C₂₂H₂₅N₃O₃S 
• 1240361-24-3 ethyl 2-[({2-[(tert-butoxycarbonyl)amino]-5-phenylthien-3-yl}carbonyl)(cyclopropylmethyl)amino]-3-(tert-butylamino)-3-oxopropanoate 
• 1240361-26-5 ethyl 2-[({2-[(tert-butoxycarbonyl)amino]-5-phenylthien-3-yl}carbonyl)(2-methoxy-ethyl)amino]-3-(tert-butylamino)-3-oxopropanoate 
• 1240361-28-7 ethyl 2-[({2-[(tert-butoxycarbonyl)amino]-5-phenylthien-3-yl}carbonyl)(phenethyl)amino]-3-(tert-butylamino)-3-oxopropanoate 
• 1240361-32-3 ethyl 2-[({2-[(tert-butoxycarbonyl)amino]-5-phenylthien-3-yl}carbonyl)(2-methoxy-ethyl)amino]-3-(cyclohexylamino)-3-oxopropanoate 

Relevant academic research and scientific papers

1,4-Thienodiazepine-2,5-diones via MCR (II): Scaffold Hopping by Gewald and Ugi-Deprotection-Cyclization Strategy

A second scaffold of 1,4-thienodiazepine-2,5-diones was discovered and is synthetically accessible from Gewald 2-aminothiophenes via Ugi-Deprotection- Cyclization (UDC) strategy. This approach yielded hybrid peptidomimetic diazepine structures with six po

1,4-Thienodiazepine-2,5-diones via MCR (I): Synthesis, Virtual Space and p53-Mdm2 Activity

1,4-Thienodiazepine-2,5-diones have been synthesized via the Ugi-Deprotection-Cyclization (UDC) approach starting from Gewald 2-aminothiophenes in a convergent and versatile manner. The resulting scaffold is unprecedented, cyclic, and peptidomimetic with four points of diversity introduced from readily available starting materials. In addition to eighteen synthesized and characterized compounds, a virtual compound library was generated and evaluated for chemical space distribution and drug-like properties. A small focused compound library of 1,4-thienodiazepine-2,5-diones has been screened for the activity against p53-Mdm2 interaction. Biological evaluations demonstrated that some compounds exhibited promising antagonistic activity.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome,